# Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants

> **NCT07250633** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Institut de Recherches Internationales Servier (I.R.I.S.)** · enrollment: 20 (estimated)

## Conditions studied

- Severe Hepatic Impairment
- Normal Hepatic Function

## Interventions

- **DRUG:** Vorasidenib 20mg

## Key facts

- **NCT ID:** NCT07250633
- **Lead sponsor:** Institut de Recherches Internationales Servier (I.R.I.S.)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07250633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07250633, "Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT07250633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*